1. Home
  2. Current Affairs
  3. News Crux
  4. SII Exports R21/Matrix-M Malaria Vaccine to Africa

SII Exports R21/Matrix-M Malaria Vaccine to Africa

  • 21 May 2024

On 20th May, 2024, Serum Institute of India (SII) commenced the export of the R21/Matrix-M malaria vaccine to Africa, marking a significant step in the global fight against malaria.

  • Developed in collaboration with the University of Oxford and Novavax, this vaccine is the second of its kind authorized for use in children in malaria-endemic regions.
  • The first shipment is destined for the Central African Republic (CAR), with subsequent deliveries planned for South Sudan and the Democratic Republic of Congo.
  • A total of 1,63,800 doses are allocated for the CAR region, with 43,200 doses already dispatched from SII's facility in Pune.
  • The R21/Matrix-M vaccine, created in partnership with the University of Oxford and using Novavax's Matrix-M adjuvant, is seen as a revolutionary tool in combating malaria.
  • The vaccine has been endorsed by the World Health Organization (WHO) for use in children and is noted for its high efficacy, cost-effectiveness, and ease of deployment.